Results 111 to 120 of about 39,159 (175)

Renal impact of sub acute lamivudine-artesunate treatment in wistar rats

, 2013
Background and objectives: Lamivudine and artesunate are life saving drugs in the treatment of HIV/HBV and malaria respectively, and available data shows artesunate having anti-tumour properties.
Anuka, Joseph A.; Department of Pharmacology & Therapeutics, Ahmadu Bello University, Zaria-Nigeria, Muktar, Haruna M.; Department of Haematology & Blood Transfusion, ABUTH, Zaria-Nigeria, Olurishe, Temidayo O.; Department of Pharmacology & Therapeutics, Ahmadu Bello University, Zaria-Nigeria, Kwanashie, Helen O.; Department of Pharmacology & Therapeutics, Ahmadu Bello University, Zaria-Nigeria, Sambo, James S.; Department of Veterinary Pathology, Ahmadu Bello University, Zaria-Nigeria   +4 more
core  

Pharmaco-economic profile, effectiveness, and safety of a dolutegravir based first line ART regimen among people living with HIV in South Gujarat. [PDF]

Indian J Med Res
Sojitra B, Patel C, Bhatt KN, Pandya S, Shah P, Shah A, Patel J, Adwani C, Panchal V.   +8 more
europepmc   +1 more source

First-line dolutegravir/lamivudine in HIV-1 infection: lymph node penetration and reservoir decline in a randomized open-label clinical trial. [PDF]

Nat Commun
Rosen EP, Bondoc S, Bailón L, Blay L, Caballero A, García-Guerrero MC, Puertas MC, Moraes-Cardoso I, Vazquez-Escobales A, Blanco J, Mothe B, Kashuba AD, Estes JD, Martinez-Picado J, Molto J, DUALITY study group.   +15 more
europepmc   +1 more source

Atypical hepatitis B surface antigen escape mutations in an HIV-positive patient in South Africa. [PDF]

S Afr J Infect Dis
Nkosi MB, van Schalkwyk M, Maponga TG, Chili YZ, Muir D, Delport PR, Hugo SS, Ismail Z, Taljaard J, van Zyl GU, Preiser W.   +10 more
europepmc   +1 more source

Multiclass HIV drug resistance: Case series of treatment-experienced PLHIV with resistance to all antiretroviral classes in Northern Uganda. [PDF]

IDCases
Kayinda F, Bakunzi LB, Okello E, Jurua C, Nasuuna EM.   +4 more
europepmc   +1 more source

Early outcomes of South African children with persistent viral non-suppression following switch to dolutegravir-based antiretroviral therapy. [PDF]

South Afr J HIV Med
Guerrini M, Maré M, Hulsman C, Greybe L, Lishman J, Edson C, Hisham T, Frigati L, Rabie H.   +8 more
europepmc   +1 more source

Brief Report: Earlier Referral to Differentiated Antiretroviral Therapy Delivery at Six Months After Initiation: A Retrospective Cohort Study in KwaZulu-Natal, South Africa. [PDF]

J Acquir Immune Defic Syndr
van der Molen JS, Tlhaku K, Lewis L, Sookrajh Y, Hobe L, Ngwenya T, Khanyile M, Khubone T, Garrett N, Brown JA, Dorward J.   +10 more
europepmc   +1 more source

Pregnancy and Neonatal Outcomes After Prenatal Exposure to Dolutegravir: Findings from the Antiretroviral Pregnancy Registry. [PDF]

J Acquir Immune Defic Syndr
Vannappagari V, Albano JD, Mofenson L, Ragone L, Cook T, Scheuerle AE, Kisare M, Short WR, Thorne C, Beckerman KP, Carneal-Frazer N, Tilson H, de Ruiter A.   +12 more
europepmc   +1 more source

Occult hepatitis B and risk of reactivation following switch to non-hepatitis B virus-active antiretroviral therapy in people with HIV. [PDF]

AIDS
Lapadula G, Soria A, Puoti M, Bonfanti P.   +3 more
europepmc   +1 more source

Voriconazole therapeutic drug monitoring and safety in HIV-infected patients with invasive fungal disease. [PDF]

Front Pharmacol
Hu L, Su Y, Hou J, Li Y, He C.
europepmc   +1 more source